Vietnam Cancer Immunotherapy Market Outlook to 2028

Vietnam Cancer Immunotherapy Market Overview

The Vietnam cancer immunotherapy market is valued at USD 570 million, based on a five-year historical analysis. This growth is driven by increasing cancer incidences in the country, technological advancements in medical research, and greater awareness of immunotherapy as an effective treatment option. Additionally, government initiatives supporting cancer treatment, such as including immunotherapies in health insurance programs, have accelerated market adoption.

The dominance of cities like Ho Chi Minh City and Hanoi in the market is primarily due to their advanced healthcare infrastructure and concentration of specialized cancer treatment centers. Both cities have leading medical research facilities and partnerships with global pharmaceutical companies, facilitating access to the latest immunotherapy treatments.

The government has encouraged Public- Private Partnerships in the healthcare sector, especially in cancer care. In 2023, the government collaborated with private hospitals and international pharmaceutical companies to establish joint ventures aimed at improving the availability of cancer immunotherapy treatments, with a projected investment of VND 150 trillion over the next five years.

Vietnam Cancer Immunotherapy Market Segmentation

By Therapy Type: The market is segmented by therapy type into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, immunomodulators, and PD-1/PD-L1 inhibitors. Monoclonal antibodies dominate the therapy segment due to their targeted mechanism of action, which provides specificity in eliminating cancer cells with fewer side effects compared to traditional treatments. Their well-established role in treating cancers such as breast cancer and colorectal cancer further strengthens their market position.

By Application: The market is also segmented by application, including lung cancer, breast cancer, colorectal cancer, melanoma, and prostate cancer. Lung cancer is the dominant segment, primarily driven by Vietnam's high smoking rates and industrial pollution levels, contributing to higher incidences of lung cancer. Immunotherapies are increasingly preferred for lung cancer treatment due to their ability to extend survival rates and reduce the recurrence of tumors.

Vietnam Cancer Immunotherapy Market Competitive Landscape

The market is dominated by a mix of local and international players, with strong competition driving innovation and market expansion.

Company Name

Established Year

Headquarters

Revenue (USD)

Employees

R&D Spending (%)

Regional Focus

Major Product

Clinical Trials

Partnerships

Nanogen Pharmaceutical

1997

Ho Chi Minh City

Pymepharco

1989

Phu Yen

Roche

1896

Basel, Switzerland

Astra Zeneca

1999

Cambridge, UK

Bristol- Myers Squibb

1887

New York, USA

Vietnam Cancer Immunotherapy Market Analysis

Market Growth Drivers

Rising Cancer Incidence in Vietnam: The increasing number of cancer cases in Vietnam is a major driver for the growth of the cancer immunotherapy market. According to the Ministry of Health, around 182,000 new cancer cases were reported in Vietnam in 2023, creating an urgent demand for advanced treatment solutions like immunotherapy.

Increased Government Healthcare Spending: The Vietnamese government is steadily increasing its healthcare budget, which stood at VND 365 trillion in 2024, to improve cancer care. This financial support is essential for the integration of costly immunotherapy treatments into the public healthcare system, making these therapies accessible to more people.

Growing Awareness of Immunotherapy: Cancer immunotherapy has gained attention due to its ability to target cancer cells more precisely. The Ministry of Health has launched nationwide campaigns to raise awareness of advanced cancer treatments, which are projected to reach over 50 million Vietnamese citizens by 2025.

Market Challenges

Regulatory Barriers: Strict regulatory approval processes for new immunotherapy drugs in Vietnam slow down market growth. As of 2024, only a handful of immunotherapy drugs had received approval from the Ministry of Health, and this process can take up to three years due to the stringent clinical testing and review process, making it difficult for new treatments to enter the market promptly.

Lack of Local Manufacturing: Most cancer immunotherapy drugs in Vietnam are imported, which contributes to their high cost. As of 2024, there are no local manufacturers producing immunotherapy drugs, leading to a reliance on expensive imports, which further increases the overall treatment cost and limits accessibility for a portion of the population.

Vietnam Cancer Immunotherapy Market Future Outlook

Over the next five years, the Vietnam cancer immunotherapy industry is expected to witness growth, driven by increased governmental investment in healthcare infrastructure and further integration of immunotherapies into mainstream cancer treatment protocols.

Future Market Opportunities

Development of Personalized Immunotherapy: Personalized cancer immunotherapy is expected to become a major focus in Vietnam's healthcare sector by 2028. Advances in genomic research will allow for the development of treatments tailored to the genetic makeup of individual patients, with clinical trials for personalized therapies projected to include 3,000 patients by 2026.

Local Production of Immunotherapy Drugs: By 2027, Vietnam is expected to establish local production facilities for cancer immunotherapy drugs, reducing the cost of these treatments by 15-20%. This development will be supported by ongoing partnerships between the government and multinational pharmaceutical companies, aiming to make immunotherapy more affordable and accessible for a broader segment of the population.
Please Note: It will take 5-7 business days to complete the report upon order confirmation